acute-myeloid-leukemia

Documents about acute-myeloid-leukemia

• PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS#874102ClinicalTrials.gov
• Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands#888073ClinicalTrials.gov
• A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy#1032132ClinicalTrials.gov
• A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients#1048064ClinicalTrials.gov
• Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma#451527ClinicalTrials.gov
• Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia#848735ClinicalTrials.gov
• Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation#856223ClinicalTrials.gov
• Study of INCB053914 in Subjects With Advanced Malignancies#914746ClinicalTrials.gov
• A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies#864620ClinicalTrials.gov
• Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin#846840ClinicalTrials.gov
• Exposure toxicity of venetoclax in acute myeloid leukemia patients in the real-life setting: impact of high exposure on delayed neutropenia#202419HAL (France)
• ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies#848503ClinicalTrials.gov
• Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML#866017ClinicalTrials.gov
• VA vs DA for Newly Diagnosed Hig-risk AML#881664ClinicalTrials.gov
• Cord Blood Microtransplantation for Treatment of Acute Myeloid Leukemia#918155ClinicalTrials.gov
• Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine#992571ClinicalTrials.gov
• Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?#994633ClinicalTrials.gov
• Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant#876044ClinicalTrials.gov
• Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission#307440ClinicalTrials.gov
• Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML#912733ClinicalTrials.gov
• Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies#835158ClinicalTrials.gov
• Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation#1047938ClinicalTrials.gov
• Different impacts of granulocyte colony‐stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type#368431OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Identification de facteurs de prédisposition aux cancers : études EOCRC et LUCID#378005HAL (France)
• A systems biology approach to find representative genes in Acute Myeloid Leukemia#406543PLOS
• MRD Response-adapted Allo-HSCT for Adverse-risk AML#800228ClinicalTrials.gov
• Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML#850085ClinicalTrials.gov
• Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML#853223ClinicalTrials.gov
• Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML#859609ClinicalTrials.gov
• Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS#861681ClinicalTrials.gov
• Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS#865205ClinicalTrials.gov
• A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS#894907ClinicalTrials.gov
• Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML#979367ClinicalTrials.gov
• ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN#981049ClinicalTrials.gov
• AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission#982225ClinicalTrials.gov
• VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML#995387ClinicalTrials.gov
• Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation#1009320ClinicalTrials.gov
• Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation#830175ClinicalTrials.gov
• Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease#803198ClinicalTrials.gov
• Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of Sepsis Scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia Treated With Intensive Chemotherapy#855130ClinicalTrials.gov
• Study Evaluating Venetoclax in Subjects With Hematological Malignancies#805982ClinicalTrials.gov
• Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML#1008611ClinicalTrials.gov
• Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS#806932ClinicalTrials.gov
• Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML#858324ClinicalTrials.gov
• Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients#898687ClinicalTrials.gov
• A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies#851055ClinicalTrials.gov
• Retraction Note: MiR-29b/Sp1/FUT4 axis modulates the malignancy of leukemia stem cells by regulating fucosylation via Wnt/β-catenin pathway in acute myeloid leukemia#1053109Europe PMC
• A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)#435760ClinicalTrials.gov
• WT1 mRNA in peripheral blood enables early prognostic stratification in AML patients receiving venetoclax and azacitidine therapy#385412OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Machine learning provides individualized prediction of outcomes after first complete remission without allo‐HSCT consolidation in adult acute myeloid leukemia—A HARMONY study.#625952NCBI PubMed Central